AC Immune (STU:IMR) Margin of Safety % (DCF Earnings Based): N/A (As of Aug. 17, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:IMR AC Immune SA STU:IMR
50 GF Score
Price €2.17
GF Value €2.99
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is AC Immune Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

AC Immune's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

STU:IMR vs TRDA, TARA, SRZN: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, AC Immune's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AC Immune Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AC Immune's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where AC Immune's Margin of Safety % (DCF Earnings Based) falls into.


STU:IMR
50GF Score
AC Immune SA STU:IMR
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is AC Immune (STU:IMR) Overvalued in 2026?

Based on GuruFocus' analysis, AC Immune stock appears to be undervalued. The current stock price of €2.17 is trading 27.6% below its estimated GF Value™ of €2.99. GuruFocus considers AC Immune to be Modestly Undervalued.

Key valuation signals for STU:IMR:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: €2.99 vs. price of €2.17 (27.6% below fair value)
  • GF Score™: 50/100 with 5 warning signs

No single metric tells the full story. See the STU:IMR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AC Immune Business Description

Other Exchanges ACIU:USA
Address EPFL Innovation Park, Building B, Lausanne, CHE, 1015
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
50GF Score

Get the complete analysis for STU:IMR

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.17
Price
€2.99
GF Value